Travere Therapeutics, Inc.
TVTXMartin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
Drugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Aug 5, 2026
4wMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
How TVTX's past catalysts played out
Irbesartan
Focal Segmental Glomerulosclerosis
Dapagliflozin
Immunoglobulin A Nephropathy
Pegtibatinase
Homocystinuria
Sparsentan
Focal Segmental Glomerulosclerosis
RE-021 (Sparsentan)
Focal Segmental Glomerulosclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Irbesartan | Phase 3 | Focal Segmental Glomerulosclerosis | - | - |
Dapagliflozin | Phase 3 | Immunoglobulin A Nephropathy | - | - |
Pegtibatinase | Phase 3 | Homocystinuria | - | - |
Sparsentan | Phase 3 | Focal Segmental Glomerulosclerosis | - | - |
RE-021 (Sparsentan) | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Travere Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Travere Therapeutics, Inc.'s (TVTX) pipeline across Phase 3, Phase 2. Its lead program is Irbesartan (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Travere Therapeutics, Inc.'s next FDA catalyst?→
Travere Therapeutics, Inc.'s (TVTX) next tracked catalyst is a Phase 2 expected June 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TVTX biotech catalysts?→
Add TVTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Travere Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.